Liquid biopsies in myeloid malignancies

Abstract

Hematologic malignancies are the most common type of cancer affecting children and young adults, and encompass diseases, such as leukemia, lymphoma, and myeloma, all of which impact blood associated tissues such as the bone marrow, lymphatic system, and blood cells. Clinical diagnostics of these malignancies relies heavily on the use of bone marrow samples, which is painful, debilitating, and not free from risks for leukemia patients. Liquid biopsies are based on minimally invasive assessment of markers in the blood (and other fluids) and have the potential to improve the efficacy of diagnostic/therapeutic strategies in leukemia patients, providing a useful tool for the real time molecular profiling of patients. The most promising noninvasive biomarkers are circulating tumor cells, circulating tumor DNA, microRNAs, and exosomes. Herein, we discuss the role of assessing these circulating biomarkers for the understanding of tumor progression and metastasis, tumor progression dynamics through treatment and for follow-up.

Keywords

Liquid biopsy / circulating tumor cells / circulating tumor DNA / exosomes / microRNAs / leukemia

References

[1] Siegel RL,Jemal A.Cancer statistics, 2016..CA Cancer J Clin2016;66:7-30

[2] Hu D.Epigenetics of hematopoiesis and hematological malignancies..Genes Dev2016;30:2021-41 PMCID:PMC5066610

[3] Fleming D.Leukemia: understanding it’s types and treatments..Oncol Nurs Advisor2012;15-20

[4] Smeltzer SC,Hinkle JL.Textbook of medical surgical nursing.2008;11th editionPhiladelphiaLippincott Williams & Wilkins410-22

[5] “Types of Leukemia.” What You Need To Know About Leukemia. National Cancer Institute, 3 Dec. 2013. Web. 24 Apr. 2014. Available from: https://www.cancer.gov/types/leukemia/hp. [Last accessed on 16 Dec 2019]

[6] Bain BJ.Leukaemia Diagnosis.2010;OxfordJohn Wiley & Sons1-63

[7] Ciesla B.Hematology in Practice.2007;PhiladelphiaF.A. Davis Co167-202

[8] Ball ED.2002;SudburyJones & Bartlett Publishers1-34

[9] Bain B.Leukaemia diagnosis.2003;Third editionOxfordJohn Wiley & Sons57-143

[10] Bain B.Blood Cells: A Practical Guide.2006;Fourth editionChichesterPublished by WileyBlackwell416-80

[11] Norman B.Diagnostic Hematology.2009;1st editionLondonSpringer9-79

[12] Foran JM.Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes..Am J Med2012;125 (7 Suppl):S6-13

[13] Barzi A.Myelodysplastic syndromes: a practical approach to diagnosis and treatment..Cleve Clin J Med2010;77:37-44

[14] Sharma SK,Seth T,Mahapatra M.Leukemia cutis: an unusual presentation..Indian J Hematol Blood Transfus2012;28:175-7 PMCID:PMC3422393

[15] Rao AG.Leukemia cutis..Indian J Dermatol2012;57:504 PMCID:PMC3519272

[16] Juliusson G,Derolf A,Möllgård L.Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry..Blood2009;113:4179-87

[17] Juliusson G,Hörstedt AS,Höglund M.Acute myeloid leukemia in the real world: why population based registries are needed..Blood2012;119:3890-9 PMCID:PMC3358248

[18] Bennett JM,Daniel MT,Galton DA.Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group..Br J Haematol1976;33:451-8

[19] Dohner H,Bloomfield CD.Acute myeloid leukemia..N Engl J Med2015;373:1136-1152

[20] Grimwade D,Moorman AV,Chatters S.Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials..Blood2010;116:354-65

[21] Estey EH.Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management..Am J Hematol2012;87:89-99

[22] Höglund M,Simonsson B.Epidemiology of chronic myeloid leukaemia: an update..Ann Hematol2015;94:S241-7

[23] Jabbour E.Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring..Am J Hematol2018;93:442-59

[24] Deininger MW,Melo JV.The molecular biology of chronic myeloid leukemia..Blood2000;96:3343-56

[25] Lugo TG,Muller AJ.Tyrosine kinase activity and transformation potency of bcr-abl oncogene products..Science1990;247:1079-82

[26] Faderl S,Estrov Z,Kurzrock R.The biology of chronic myeloid leukemia..N Engl J Med1999;341:164-72

[27] Sawyers CL.Chronic myeloid leukemia..N Engl J Med1999;340:133040

[28] Geary CG.The story of chronic myeloid leukaemia..Br J Haematol2000;110:2-11

[29] Baccarani M,Gugliotta G,Rosti G.Treatment - recommendations for chronic myeloid leukemia..Mediterr J Hematol Infect Dis2014;6:e2014005 PMCID:PMC3894838

[30] Fefer A,Thomas ED,Ramberg R.Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin..N Engl J Med1979;300:333-7

[31] Goldman JM,McCarthy DM,Hows JM.Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia..Lancet1982;2:623-5

[32] Speck B,Champlin R,Herzig RH.Allogeneic bone-marrow transplantation for chronic myelogenous leukaemia..Lancet1984;1:665-8

[33] Talpaz M,Mavligit GM.Leukocyte interferon-induced myeloid cytoreduction in chronic myelogenous leukemia..Blood1983;62:689-92

[34] Hochhaus A,Guilhot F,Branford S.Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia..Leukemia2009;23:1054-61

[35] Druker BJ,O’Brien SG,Kantarjian H.Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia..N Engl J Med2006;355:2408-17

[36] Cortes J.Chronic myeloid leukemia: sequencing of TKI therapies..Hematology Am Soc Hematol Educ Program2016;2016:164-9 PMCID:PMC6142480

[37] Neukirchen J,Strupp C,Aul C.Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry..Leuk Res2011;35:1591-6

[38] Williamson PJ,Reynolds PJ,Oscier DG.Establishing the incidence of myelodysplastic syndrome..Br J Haematol1994;87:743-5

[39] Kuendgen A,Aivado M,Haas R.Myelodysplastic syndromes in patients younger than age 50..J Clin Oncol2006;24:5358-65

[40] Geyh S,Cadeddu RP,Brückner B.Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells..Leukemia2013;27:1841-51

[41] Germing U,Strupp C,Hossfeld DK.Myelodysplastische syndrome: neue WHO-klassifikation und aspekte zur pathogenese, prognose and therapie..Dtsch Arztebl2001;98:A2272-8

[42] Germing U,Niemeyer CM,Bennett JM.Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes..Ann Hematol2008;87:691-9

[43] Greenberg P,LeBeau MM,Morel P.International scoring system for evaluating prognosis in myelodysplastic syndromes..Blood1997;89:2079-88

[44] Greenberg PL,Schanz J,Garcia-Manero G.Revised international prognostic scoring system for myelodysplastic syndromes..Blood2012;120:2454-65 PMCID:PMC4425443

[45] Arber DA,Hasserjian R,Borowitz MJ.The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia..Blood2016;127:2391-405

[46] Diamantis A,Koutselini H.Fine-needle aspiration (FNA) biopsy: historical aspects. Folia Histochem..Cytobiol2009;47:191-7

[47] Crowley E,Loupakis F.Liquid biopsy: monitoring cancergenetics in the blood..Nat Rev Clin Oncol2013;10:472-84

[48] Perakis S.Emerging concepts in liquid biopsies..BMC Med2017;15:75 PMCID:PMC5382440

[49] Siravegna G,Siena S.Integrating liquid biopsies into the management of cancer..Nat Rev Clin Oncol2017;14:531-48

[50] Kubaczkova V,Sedlarikova L,Sevcikova S.Cell- free DNA - Minimally invasive marker of hematological malignancies..Eur J Haematol2017;99:291-9

[51] Buder A,Filipits M.The potential of liquid biopsies..Curr Opin Oncol2016;28:130-4

[52] Rolfo C,Hong D,Mertens I.Liquid biopsies in lung cancer: the new ambrosia of researchers..Biochim Biophys Acta2014;1846:539-46

[53] Domínguez-Vigil I,Wang J,Barrera-Saldaña H.The dawn of the liquid biopsy in the fight against cancer..Oncotarget2018;9:2912-22 PMCID:PMC5788692

[54] Bettegowda C,Leary R,Wang Y.Detection of circulating tumor DNA in early- and late-stage human malignancies..Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[55] Zheng D,Zhang MZ,Wang JY.Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance..Sci Rep2016;6:20913 PMCID:PMC4751431

[56] Novello S,Califano R,Ekman S.Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up..Ann Oncol2016;27:v1-v27

[57] Diaz LA.Liquid biopsies: genotyping circulating tumor DNA..J Clin Oncol2014;32:579-86 PMCID:PMC4820760

[58] Stroun M,Lederrey C,Anker P.About the possible origin and mechanism of circulating DNA apoptosis and active DNA release..Clin Chim Acta2001;313:139-42

[59] Jahr S,Englisch S,Fackelmayer FO.DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells..Cancer Res2001;61:1659-65

[60] Mouliere F,Arnau Peyrotte E,Ychou M.High fragmentation characterizes tumour-derived circulating DNA..PLoS One2011;6:e23418 PMCID:PMC3167805

[61] Bergsmedh A,Henriksson M,Folkman MJ.Horizontal transfer of oncogenes by uptake of apoptotic bodies..Proc Natl Acad Sci U S A2001;98:6407-11 PMCID:PMC33481

[62] Underhill HR,Hellwig S,Daza R.Fragment length of circulating tumor DNA..PLoS Genet2016;12:e1006162 PMCID:PMC4948782

[63] Cheng F,Qian C.Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer..Oncotarget2016;7:48832-41 PMCID:PMC5217053

[64] Li J,Xia S,Du M.Cell-free DNA copy number variations in plasma from colorectal cancer patients..Mol Oncol2017;11:1099-111 PMCID:PMC5537711

[65] Soave A,Hillebrand T,Weisbach L.Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study..Oncotarget2017;8:56398-407 PMCID:PMC5593570

[66] Husain H,Bui N,Gomez G.Cell-free DNA from ascites and pleural effusions: molecular insights into genomic aberrations and disease biology..Mol Cancer Ther2017;16:948-55

[67] Li Z,Tang L,Chen M.Methylation analysis of plasma cell-free DNA for breast cancer early detection using bisulfite next-generation sequencing..Tumour Biol2016;37:13111-9

[68] Fleischhacker M.Circulating nucleic acids (CNAs) and cancer-A survey..Biochim Biophys Acta2007;1775:181-232

[69] Siravegna G.Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance..Genome Biol2014;15:449 PMCID:PMC4281953

[70] Schwarzenbach H,Pantel K.Cell-free nucleic acids as biomarkers in cancer patients..Nat Rev Cancer2011;11:426-37

[71] Chan KC,Lui WB,Lo YM.Effects of preanalytical factors on the molecular size of cell-free DNA in blood..Clin Chem2005;51:781-4

[72] Su YH,Aiamkitsumrit B,Block TM.Detection of a K-ras mutation in urine of patients with colorectal cancer..Cancer Biomark2005;1:177-82

[73] Wang Y,Mulvey CL,Schaefer J.Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas..Sci Transl Med2015;7:293ra104 PMCID:PMC4587492

[74] De Mattos-Arruda L,Ng CK,Martínez-Ricarte F.Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma..Nat Commun2015;6:8839 PMCID:PMC5426516

[75] Barra GB,de Almeida Vasques J,Nery LF.EDTA-mediated inhibition of DNases protects circulating cell-free DNA from ex vivo degradation in blood samples..Clin Biochem2015;48:976-81

[76] EI Messaoudi S,Mouliere F.Circulating cell free DNA: preanalytical considerations..Clin Chim Acta2013;424:222-30

[77] Parpart-Li S,Popoli M,Tucker L.The effect of preservative and temperature on the analysis of circulating tumor DNA..Clin Cancer Res2017;23:2471-7

[78] Mandel P.Les acides nucléiques du plasma sanguin chez l’homme..C R Seances Soc Biol Fil1948;142:241-3(in French)

[79] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy..Cancer Res1977;37:646-50

[80] Vasioukhin V,Maurice P,Lederrey C.Point mutations of the N- ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia..Br J Haematol1994;86:774-9

[81] Osborne CM,Devers P,Hayden MA.Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease..Prenat Diagn2013;33:609-11

[82] Cell-free DNA screening for fetal aneuploidy..Obs Gynecol2015;126:e31-7

[83] Heitzer E,Geigl JB.Circulating tumor DNA as a liquid biopsy for cancer..Clin Chem2015;61:112-23

[84] Marzese DM,Hoon DSB.Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients..Expert Rev Mol Diagn2013;13:827-44

[85] Han X,Sun Y.Circulating tumor DNA as biomarkers for cancer detection..Genomics Proteomics Bioinformatics2017;15:59-72 PMCID:PMC5414889

[86] Martinez-Galan J,Nunez L-PJ,Ruiz De Almodovar J.ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients..BMC Cancer2014;14:59 PMCID:PMC3922625

[87] Church TR,Lofton-Day C,Burger M.Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer..Gut2014;63:317-25 PMCID:PMC3913123

[88] Cohen JD,Wang Y,Afsari B.Detection and localization of surgically resectable cancers with a multi-analyte blood test..Science2018;359:926-30 PMCID:PMC6080308

[89] Stevenson K,Sougnez C,Sivachenko A.Evolution and impact of subclonal mutations in chronic lymphocytic leukemia..Cell2013;152:714-26 PMCID:PMC3575604

[90] Abbosh C,Wilson GA,Constantin T.Phylogenetic ctDNA analysis depicts early stage lung cancer evolution..Nature2017;545:446-51 PMCID:PMC5812436

[91] Imamura T,Ichikawa D,Miyamae M.Liquid biopsy in patients with pancreatic cancer: circulating tumor cells and cell-free nucleic acids..World J Gastroenterol2016;22:5627-41 PMCID:PMC4932201

[92] Morgan CD.Observations on cancer: its pathology, and its relations to the organism and to other morbid growths..Lancet1874;103:325-9

[93] Ashworth T.A case of cancer in which cells similar to those in the tumors were seen in the blood after death..Aust Med J1869;14:146-7

[94] Parkinson DR,Petty BG,Cristofanilli M.Considerations in the development of circulating tumor cell technology for clinical use..J Transl Med2012;10:138 PMCID:PMC3478228

[95] Young R,Billiot F,Barthelemy A.Circulating tumor cells in lung cancer..Acta Cytol2012;56:655-60

[96] Krebs MG,Carter L,Blackhall FH.Molecular analysis of circulating tumour cellsbiology and biomarkers..Nat Rev Clin Oncol2014;11:129-44

[97] Lianidou ES,Markou A.Circulating tumor cells as promising novel biomarkers in solid cancers..Crit Rev Clin Lab Sci2014;51:160-71

[98] De Wit S,Terstappen LW.Detection of circulating tumor cells..Scientifica2014;2014:819362

[99] Hayes DF,Budd GT,Stopeck A.Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival..Clin Cancer Res2006;12:4218-24

[100] Alix-Panabières C.Circulating tumor cells: liquid biopsy of cancer..Clin Chem2013;59:110-8

[101] Nagrath S,Maheswaran S,Irimia D.Isolation of rare circulating tumour cells in cancer patients by microchip technology..Nature2007;450:1235-9 PMCID:PMC3090667

[102] Marrugo-Ramírez J,Samitier J.Blood-based cancer biomarkers in liquid biopsy: a promising non-invasive alternative to tissue biopsy..Int J Mol Sci2018;19:2877 PMCID:PMC6213360

[103] Ozkumur E,Ciciliano JC,Miyamoto DT.Inertial focusing for tumor antigen-dependent and-independent sorting of rare circulating tumor cells..Sci Transl Med2013;5:179ra47 PMCID:PMC3760275

[104] Lianidou ES.Gene expression profiling and DNA methylation analyses of CTCs..Mol Oncol2016;10:431-42 PMCID:PMC5528973

[105] Lianidou ES.Molecular assays for the detection and characterization of CTCs..Recent Results Cancer Res2012;195:111-23

[106] Markou A,Paraskevopoulos P,Świerczewska M.Multiplex gene expression profiling of in vivo isolated circulating tumor cells in high risk prostate cancer patients..Clin Chem2018;64:297-306

[107] Strati A,Papaxoinis G,Zavridou M.Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma..Ann Oncol2017;28:1923-33

[108] Keup C,Aktas B,Kolberg HC.RNA profiles of circulating tumor cells and extracellular vesicles for therapy stratification of metastatic breast cancer patients..Clin Chem2018;64:1054-62

[109] König L,Bittner A-K,Wagner B.Elevated levels of extracellular vesicles are associated with therapy failure and disease progression in breast cancer patients undergoing neoadjuvant chemotherapy..Oncoimmunology2017;7:e1376153 PMCID:PMC5739576

[110] Bredemeier M,Mach P,Sjöback R.Gene expression signatures in circulating tumor cells correlate with response to therapy in metastatic breast cancer..Clin Chem2017;63:1585-93

[111] Chebouti I,Buderath P,Hauch S.EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy..Oncotarget2017;8:48820-31 PMCID:PMC5564727

[112] Reijm EA,Smid M,Mostert B.An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patients..BMC Cancer2016;16:123 PMCID:PMC4759736

[113] Gorges TM,Röck K,Müller V.Accession of tumor heterogeneity by multiplex transcriptome profiling of single circulating tumor cells..Clin Chem2016;62:1504-15

[114] Markou A,Sourvinou I,Kounelis S.Direct comparison of metastasis-related miRNAs expression levels in circulating tumor cells, corresponding plasma, and primary tumors of breast cancer patients..Clin Chem2016;62:1002-11

[115] Sieuwerts AM,Bolt-de Vries J,Mostert B.Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR..Breast Cancer Res Treat2009;118:455-68

[116] Frontela Noda M.MicroRNAs in cancer: from research to clinical practice..Rev Cubana Med2012;51:325-35(in Spanish)

[117] Etheridge A,Hood L,Wang K.Extracellular microRNA: a new source of biomarkers..Mutat Res2011;717:85-90 PMCID:PMC3199035

[118] Resnick KE,Hagan JP,Croce CM.The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform..Gynecol Oncol2009;112:55-9

[119] Calin GA,Shimizu M,Zupo S.Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia..Proc Natl Acad Sci U S A2002;99:15524-9 PMCID:PMC137750

[120] Calin GA,Cimmino A,Shimizu M.A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia..N Engl J Med2005;353:1793-801

[121] Croce CM.Causes and consequences of microRNA dysregulation in cancer..Nat Rev Genet2009;10:704-14 PMCID:PMC3467096

[122] Takamizawa J,Yanagisawa K,Osada H.Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival..Cancer Res2004;64:3753-6

[123] Kasinski AL.Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy..Nat Rev Cancer2011;11:849-64 PMCID:PMC4314215

[124] Weber JA,Zhang SL,Huang KH.The MicroRNA spectrum in 12 body fluids..Clin Chem2010;56:1733-41 PMCID:PMC4846276

[125] Wang K,Cho JH,Baxter D.Comparing the MicroRNA spectrum between serum and plasma..PloS One2012;7:e41561 PMCID:PMC3409228

[126] Calin GA.MicroRNA signatures in human cancers..Nat Rev Cancer2006;6:857-66

[127] Mitchell PS,Kroh EM,Wyman SK.Circulating microRNAs as stable blood-based markers for cancer detection..Proc Natl Acad Sci U S A2008;105:10513-8 PMCID:PMC2492472

[128] Chen X,Ma L,Yin Y.Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases..Cell Res2008;18:997-1006

[129] Filipowicz W,Sonenberg N.Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?.Nat Rev Genet2008;9:102-14

[130] Ichikawa D,Konishi H.Circulating microRNA in digestive tract cancers..Gastroenterology2012;142:1074-8.e1071

[131] Arroyo JD,Kroh EM,Pritchard CC.Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma..Proc Natl Acad Sci USA2011;108:5003-8 PMCID:PMC3064324

[132] Vickers KC,Shoucri BM,Remaley AT.MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins..Nat Cell Biol2011;13:423-33 PMCID:PMC3074610

[133] Kosaka N,Ochiya T.Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis..Cancer Sci2010;101:2087-92

[134] Hasselmann DO,Tilgen W.Extracellular tyrosinase mRNA within apoptotic bodies is protected from degradation in human serum..Clin Chem2001;47:1488-9

[135] Cocucci E,Meldolesi J.Shedding microvesicles: artefacts no more..Trends Cell Biol2009;19:43-51

[136] Antolin S,Blanco-Calvo M,Lorenzo-Patino MJ.Circulating miR-200c and miR-141 and outcomes in patients with breast cancer..BMC Cancer2015;15:297 PMCID:PMC4405843

[137] Zanutto S,Ghilotti M,Ravagnani F.Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer..Br J Cancer2014;110:1001-7 PMCID:PMC3929896

[138] Zhang J,Zhang C,Fu H.Circulating MiR16-5p and MiR-19b-3p as two novel potential biomarkers to indicate progression of gastric cancer..Theranostics2015;5:733-45 PMCID:PMC4402497

[139] Zhao Y,Yao L,Teng C.Circulating microRNAs: promising biomarkers involved in several cancers and other diseases..DNA Cell Biol2017;36:77-94

[140] Kawaguchi T,Ichikawa D,Tsujiura M.Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer..Br J Cancer2013;108:361-9 PMCID:PMC3566805

[141] Mirzaei HR,Mohammadi M,Salehi H.Circulating microRNAs in hepatocellular carcinoma: potential diagnostic and prognostic biomarkers..Curr Pharm Des2016;22:5257-69

[142] Caivano A,Simeon V,Dinarelli S.MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report..Cell Oncol (Dordr)2017;40:97-103

[143] Ono S,Nagahara M.Circulating microRNA biomarkers as liquid biopsy for cancer patients: pros and cons of current assays..J Clin Med2015;4:1890-907 PMCID:PMC4626661

[144] Mashouri L,Aref AR,Molaei F.Exosomes: composition, biogenesis, and mechanisms in cancer metastasis and drug resistance..Mol Cancer2019;18:75 PMCID:PMC6444571

[145] Simpson RJ,Moritz RL.Exosomes: proteomic insights and diagnostic potential..Expert Rev Proteom2009;6:267-83

[146] Roma-Rodrigues C,Baptista PV.Exosome in tumour microenvironment: overview of the crosstalk between normal and cancer cells..Biomed Res Int2014;2014:179486 PMCID:PMC4055162

[147] Spugnini EP,Di Raimo R,Fais S.A role of tumor-released exosomes in paracrine dissemination and metastasis..Int J Mol Sci2018;19:E3968 PMCID:PMC6321583

[148] Yousafzai NA,Wang Z,Zhu L.Exosome mediated multidrug resistance in cancer..Am J Cancer Res2018;8:2210-26 PMCID:PMC6291647

[149] Li I.Exosomes in the tumor microenvironment as mediators of cancer therapy resistance..Mol Cancer2019;18:32 PMCID:PMC6397467

[150] Guo Y,Liu J,Zhou Q.Effects of exosomes on pre-metastatic niche formation in tumors..Mol Cancer2019;18:39 PMCID:PMC6413442

[151] Qiao F,Yan J,Zong Y.Role of tumor-derived extracellular vesicles in cancer progression and their clinical applications (Review)..Int J Oncol2019;54:1525-33

[152] Roma-Rodrigues C,Baptista PV.Targeting tumor microenvironment for cancer therapy..Int J Mol Sci2019;20:E840 PMCID:PMC6413095

[153] Logozzi M,Mizzoni D,Fais S.Extracellular acidity and increased exosome release as key phenotypes of malignant tumors..Cancer Metastasis Rev2019;38:93-101

[154] Weston WW,Temple HT.The relationship between exosomes and cancer: implications for diagnostics and therapeutics..BioDrugs2019;33:137-58

[155] Aghebati-Maleki A,Baghbanzadeh A,Noorolyai S.Implications of exosomes as diagnostic and therapeutic strategies in cancer..J Cell Physiol2019;234:21694-706

[156] Bellassai N,Jungbluth V.Surface plasmon resonance for biomarker detection: advances in non-invasive cancer diagnosis..Front Chem2019;7:570 PMCID:PMC6695566

[157] Dorayappan KDP,Hisey CL,Smith BQ.A microfluidic chip enables isolation of exosomes and establishment of their protein profiles and associated signaling pathways in ovarian cancer..Cancer Res2019;79:3503-13

[158] Li P,Han W,Bao W.Ultrasensitive and reversible nanoplatform of urinary exosomes for prostate cancer diagnosis..ACS Sens2019;4:1433-41

[159] Taylor DD.MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer..Gynecol Oncol2008;10:13-21

[160] Meng X,Milde-Langosch K,Pantel K H.Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer..Oncotarget2016;7:16923-35 PMCID:PMC4941360

[161] Giannopoulou L,Kasimir-Bauer S.Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes..Transl Res2019;205:77-91

[162] Li Y,Qiu F.Proteomic identification of exosomal LRG1: a potential urinary biomarker for detecting NSCLC..Electrophoresis2011;32:1976-83

[163] Weber DG,Casjens S,Pesch B.Evaluation of long noncoding RNA MALAT1 as a candidate blood-based biomarker for the diagnosis of non-small cell lung cancer..BMC Res Notes2013;6:518 PMCID:PMC4029199

[164] Liu S,Luo J,Lu J.Roles of exosomes in the carcinogenesis and clinical therapy of non-small cell lung cancer..Biomed Pharmacother2019;111:338-46

[165] Ogata-Kawata H,Kurioka D,Yamada Y.Circulating exosomal microRNAs as biomarkers of colon cancer..PLoS One2014;9:e92921 PMCID:PMC3976275

[166] Mousavi S,Hassanian SM,Mardani R.Tumor-derived exosomes: potential biomarkers and therapeutic target in the treatment of colorectal cancer..J Cell Physiol2019;234:12422-32

[167] Melo SA,Kahlert C,Gammon ST.Glypican-1 identifies cancer exosomes and detects early pancreatic cancer..Nature2015;523:177-82 PMCID:PMC4825698

[168] Zhou B,Cheng YG,Hu SY.Early detection of pancreatic cancer: where are we now and where are we going?.Int J Cancer2017;141:231-41

[169] Kaplan RN,Zacharoulis S,Vincent L.VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche..Nature2005;438:820-7 PMCID:PMC2945882

[170] Kaplan RN,Lyden D.Bone marrow cells in the ‘pre-metastatic niche’: within bone and beyond..Cancer Metastasis Rev2006;25:521-9

[171] Hoshino A,Shen TL,Hashimoto A.Tumour exosome integrins determine organotropic metastasis..Nature2015;527:329-35 PMCID:PMC4788391

[172] Costa-Silva B,Ocean AJ,Zhang H.Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver..Nat Cell Biol2015;17:816-26 PMCID:PMC5769922

[173] Peinado H,Matei IR,Hoshino A.Pre-metastatic niches: organ-specific homes for metastases..Nat Rev Cancer2017;17:302-17

[174] Li J,Zhou X.The role of exosomal shuttle RNA (esRNA) in lymphoma..Crit Rev Oncol Hematol2019;137:27-34

[175] Yang C,Liu J,Yu S.Focus on exosomes: novel pathogenic components of leukemia..Am J Cancer Res2019;9:1815-29 PMCID:PMC6726990

[176] Umezu T,Kuroda M.Leukemia cell to endothelial cell communication via exosomal miRNAs..Oncogene2013;32:2747-55

[177] Tadokoro H,Ohyashiki K,Ohyashiki JH.Exosomes derived from hypoxic leukemia cells enhance tube formation in endothelial cells..J Biol Chem2013;288:34343-51 PMCID:PMC3843049

[178] Mineo M,Taverna S,De Leo G.Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion..Angiogenesis2012;15:33-45 PMCID:PMC3595015

[179] Taverna S,Saieva L,Giallombardo M.Exosomal shuttling of miR-126 in endothelial cells modulates adhesive and migratory abilities of chronic myelogenous leukemia cells..Mol Cancer2014;13:169 PMCID:PMC4105877

[180] Taverna S,Saieva L,Santoro A.Role of exosomes released by chronic myelogenous leukemia cells in angiogenesis..Int J Cancer2012;130:2033-43 PMCID:PMC3236253

[181] Korkolopoulou P,Kavantzas N,Thymara I.Clinicopathologic correlations of bone marrow angiogenesis in chronic myeloid leukemia: a morphometric study..Leukemia2003;17:89-97

[182] Vinhas R,Fernandes AR.Nanoparticles - emerging potential for managing leukemia and lymphoma..Front Bioeng Biotechnol2017;5:79 PMCID:PMC5741836

[183] Rogers A,Manshouri T,Jilani I.Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia..Blood2004;103:2799-801

[184] Mouliere F,Pang D,Thierry AR.Multi- marker analysis of circulating cell- free DNA toward personalized medicine for colorectal cancer..Mol Oncol2014;8:927-41 PMCID:PMC5528519

[185] Gao YJ,Yang ZL,Zuo Y.Increased integrity of circulating cell- free DNA in plasma of patients with acute leukemia..Clin Chem Lab Med2010;48:1651-6

[186] Hocking J,Kalff A.Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies..Cancer Biol Med2016;13:215-25 PMCID:PMC4944540

[187] Koutova L,Pazourkova E,Svobodova I.The impact of standard chemotherapy on miRNA signature in plasma in AML patients..Leuk Res2015;39:1389-95

[188] Cornelissen JJ,Schlenk RF,Bornhäuser M.The European LeukemiaNet AML working party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach..Nat Rev Clin Oncol2012;9:579-90

[189] Quan J,Yang Z,Xian JR.Quantitative detection of circulating nucleophosmin mutations DNA in the plasma of patients with acute myeloid leukemia..Int J Med Sci2015;12:17-22 PMCID:PMC4278871

[190] Falini B,Tiacci E,Rosati R.Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype..N Engl J Med2005;352:254-66

[191] Nakamura S,Shimizu E,Kondoh K.Prognostic impact of circulating tumor DNA status post-allogeneic hematopoietic stem cell transplantation in AML and MDS..Blood2019;133:2682-95

[192] Iriyama C,Hoshino H,Furukawa-Hibi Y.Using peripheral blood circulating DNAs to detect CpG global methylation status and genetic mutations in patients with myelodysplastic syndrome..Biochem Biophys Res Commun2012;419:662-9

[193] Suzuki Y,Nakamura F,Shirahata-Adachi M.Peripheral blood cell- free DNA is an alternative tumor DNA source reflecting disease status in myelodysplastic syndromes..Cancer Sci2016;107:1329-37 PMCID:PMC5021037

[194] Yeh P,Ftouni S,Sinha D.Molecular disease monitoring using circulating tumor DNA in myelodysplastic syndromes..Blood2017;129:1685-90

[195] Corrado C,Raimondo S,De Leo G.Chronic myelogenous leukemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor..J Cell Mol Med2016;20:1829-39 PMCID:PMC4876029

[196] Raimondo S,Corrado C,Flugy A.Chronic myeloid leukemiaderived exosomes promote tumor growth through an autocrine mechanism..Cell Commun Signal2015;13:8 PMCID:PMC4320527

[197] Heidary M,Ulz P,Petru E.The dynamic range of circulating tumor DNA in metastatic breast cancer..Breast Cancer Res2014;16:421 PMCID:PMC4303230

[198] Ulz P,Heitzer E.Detection of circulating tumor DNA in the blood of cancer patients: an important tool in cancer chemoprevention..Methods Mol Biol2016;1379:45-68

[199] Van Roy N,Menten B,Vandeputte C.Shallow whole genome sequencing on circulating cell-free DNA allows reliable non-invasive copy number profiling in neuroblastoma patients..Clin Cancer Res2017;

[200] Adalsteinsson VA,Freeman SS,Stover DG.Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors..Nat Commun2017;8:1324 PMCID:PMC5673918

[201] Stover DG,Ha G,Barry B.Genomewide copy number analysis of chemotherapy resistant metastatic triple-negative breast cancer from cell-free DNA..J Clin Oncol2018;78:

[202] Wang J.Applications of DNA-based liquid biopsy for central nervous system neoplasms..J Mol Diagn2017;19:24-34

[203] Ilie M,Long E,Selva E.Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine?.Ann Trans Med2014;2:107 PMCID:PMC4245510

[204] Newman AM,To J,Eclov NC.An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage..Nat Med2014;20:548-54 PMCID:PMC4016134

[205] Molina-Vila MA,Giménez-Capitán A,Garzón M.Liquid biopsy in non-small cell lung cancer..Front Med2016;3:69 PMCID:PMC5179978

[206] Diehl F,Choti MA,Goodman S.Circulating mutant DNA to assess tumor dynamics..Nat Med2008;14:985-90 PMCID:PMC2820391

[207] Kidess E.Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?.Genome Med2013;5:70 PMCID:PMC3979136

[208] Diaz LA.Liquid biopsies: genotyping circulating tumor DNA..J Clin Oncol2014;32:579-86 PMCID:PMC4820760